Fatty liver disease can involve liver scarring (fibrosis) even when ALT, a common liver enzyme on blood tests, is within the lab’s normal range. Clinicians therefore assess fibrosis risk using more than ALT alone. They often start with the FIB-4 score, calculated from routine blood results and your age, then consider liver elastography or specialist review when the score or your health history warrants it.
This stepwise approach helps identify people who may have advanced fibrosis without sending everyone straight to an invasive test. A low-risk result is reassuring, but it is not a guarantee that scarring is absent.
Why Normal ALT Does Not Rule Out Fibrosis
ALT and AST are enzymes that can rise when liver cells are injured. They are not direct measurements of scar tissue. In MASLD—metabolic dysfunction-associated steatotic liver disease, previously called NAFLD—enzyme levels may be normal or only mildly raised even when fibrosis is present. So a normal ALT result alone cannot tell you whether your liver has scarring.
That distinction matters if imaging has shown hepatic steatosis (fat in the liver), or if you have cardiometabolic risk factors such as type 2 diabetes or obesity. The 2024 joint European EASL-EASD-EASO guideline recommends fibrosis case-finding for people with cardiometabolic risk factors, abnormal liver enzymes, and/or imaging signs of steatosis, with particular attention to people with type 2 diabetes or obesity plus another metabolic risk factor. The goal is to assess scarring risk, not to assume that everyone with fatty liver will develop advanced disease.
How FIB-4 Helps Assess Fatty Liver Disease
FIB-4 uses your age, AST, ALT and platelet count. It is a risk-assessment score, not a scan or a diagnosis. Many clinical pathways use a result below 1.3 to indicate lower risk of advanced fibrosis and above 2.67 to indicate higher risk. Results between those values are often considered indeterminate and may lead to a second test. The exact thresholds and next steps can vary by guideline and clinical context.
Age affects the score, so interpretation can be less straightforward in older adults. Some pathways use age-adjusted thresholds, while research has questioned whether raising the threshold is appropriate in every setting. If your result is near a cutoff, ask your clinician how your age, other health conditions and local guidance affect what it means. A low score can reduce concern about advanced fibrosis, but it does not rule out every degree of scarring.
When Liver Elastography or Specialist Review May Follow
If FIB-4 is not clearly low, a clinician may arrange liver elastography, often transient elastography. This test uses vibrations and ultrasound to estimate liver stiffness; it does not take a tissue sample. A higher stiffness measurement can raise concern about fibrosis, but it is not a perfect stand-alone answer. Results need interpretation alongside your health history and other tests, and thresholds depend on the test and clinical setting.
A high or unclear FIB-4 result, a concerning elastography result, or disagreement between tests may prompt review by a liver specialist. Further assessment can clarify risk and whether any additional testing is appropriate. You can ask which result led to the next step and what the test is intended to assess. For a related explanation of how diabetes can affect this pathway, see how doctors check for liver scarring with type 2 diabetes.
What FIB-4 Can—and Cannot—Tell You
FIB-4 is useful partly because it relies on routine information, but it can misclassify some people. A 2025 multicentre study by Martin Franck and colleagues examined 458 adults with biopsy-proven MASLD treated at five university hospitals in Germany. When the researchers assessed significant fibrosis (stage F2 or higher), they reported false-positive and false-negative rates of 43% and 26% for FIB-4. The study’s participants had already undergone biopsy, so its results should not be read as the error rate for everyone with fatty liver. Also, the study examined significant fibrosis, while common FIB-4 pathways are primarily designed to assess risk of advanced fibrosis. The different targets matter when interpreting the findings.
In practice, FIB-4 is usually a first step, not the final word. If you have MASLD alongside type 2 diabetes, obesity or another metabolic risk factor, ask your clinician whether fibrosis risk has been assessed and whether your results call for follow-up. Seek medical advice to interpret your own tests; this guide cannot determine your individual risk.
